Dr. Reddy's Laboratories in the news
Global pharmaceutical products manufacturing
Tamtam found 20 recent articles about Dr. Reddy's Laboratories.
- Dr. Reddy's Laboratories concludes USFDA inspection with 'Voluntary Action Indicated' outcome
Dr. Reddy's Laboratories concluded a USFDA inspection of its Hyderabad facility with a 'Voluntary Action Indicated' outcome, officially closing the review.
- Dr Reddy’s gets FDA tentative nod for HIV prevention drug
Dr. Reddy's Laboratories secured tentative FDA approval for its twice-yearly, long-acting HIV prevention drug, lenacapavir, enabling wider access to this highly effective antiviral medication.
- Dr Reddy's Share Price : Q2 में मुनाफा 36% घटने का बावजूद शेयर में आई जोरदार तेजी, जानिए क्या है ब्रोकरेज की राय
Dr. Reddy's Laboratories shares gained despite a profit decline, due to positive brokerage outlooks on margin improvement and better-than-expected Q2 results.
- 50 पैसे से भी कम कीमत, फिर भी बन गया देश का पहला ₹100 करोड़ का फार्मा ब्रांड! गैस की इस दवा की कहानी है दिलचस्प
Dr. Reddy's Laboratories achieved a significant milestone with Omez (Omeprazole) in 1991, becoming India's first pharmaceutical brand to reach 100 crores in sales through an affordable generic approach.
- Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
Dr. Reddy's Laboratories reported double-digit growth in its base business, despite a 1.5% revenue decline due to lower Lenalidomide sales, while resolving Semaglutide supply issues and advancing its complex generics pipeline.
- Dr Reddy's Q2 Result: 36% गिरा मुनाफा, खास वजह से घटा रेवेन्यू, अब 26 अक्टूबर को शेयर फोकस में
Dr. Reddy's Laboratories' Q2 net profit fell 36% year-on-year, despite exceeding estimates, due to slow Lenalidomide sales in North America.
- Dr Reddy’s set to resume Semaglutide supplies in Q3 after production disruption
Dr. Reddy's Laboratories will resume semaglutide supplies in Q3 FY27 after resolving an impurity issue, starting with Canada and other emerging markets, while also launching new brands and managing a decline in Q2 FY27 revenue.
- Dr Reddys Lab Q2 Results: कंपनी का नेट प्रॉफिट 36% गिरकर 925 करोड़ रहा, रेवेन्यू भी 2% घटी
Dr. Reddy's Laboratories reported a 36% decline in net profit and a 2% decrease in revenue for the second quarter of the current fiscal year.
- Dr Reddy’s Q2 results: Net Profit falls 31% to Rs 925 crore, US sales drop 23%
Dr. Reddy's Laboratories' Q2 net profit fell 31% to Rs 925 crore, with US sales down 23% due to competition, while Indian market revenue grew 17.2%.
- Trade Spotlight: How should you trade Gabriel India, Dr Reddys Labs, MCX India, Craftsman Automation, Solar Industries, and others on October 13?
The document provides trading recommendations for various stocks including Gabriel India, Dr Reddy's Laboratories, and Cipla, given the current market pressure.
- Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Dr. Reddy's Laboratories shares rose after receiving an upgrade from BNP Paribas, based on multiple financial and operational metrics.
- Dr. Reddy’s (NYSE: RDY) schedules analyst and investor meetings for September 2026
Dr. Reddy's Laboratories will participate in investor meetings in September 2026, hosted by ICICI Securities and Bank of America.
- A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).
Dr. Reddy's Laboratories filed a Form 6-K with the SEC in October 2026, affirming its status as a foreign private issuer and its filing of annual reports under Form 20-F.
- Dr Reddy’s Laboratories: Two major announcements to impact stock in near term
Dr. Reddy's Laboratories is addressing two US FDA observations at its FTO-11 manufacturing facility in Andhra Pradesh after a recent inspection.
- Dr Reddy’s, Nestlé, Amazon और Flipkart को नोटिस, प्रोटीन सप्लीमेंट के स्वास्थ्य संबंधी दावों पर सवाल
The FSSAI issued notices to Dr. Reddy's Laboratories and other companies over misleading health claims on protein supplements, particularly for 'Celevida GLP+', questioning various nutritional benefits and promotional statements.
- Dr Reddy’s Laboratories receives two observations for Andhra Pradesh facility
Dr Reddy’s Laboratories received two observations from the USFDA after an inspection at its Andhra Pradesh manufacturing facility.
- Dr. Reddy’s facility in Andhra Pradesh gets 2 U.S. FDA observations
Dr. Reddy's Laboratories' manufacturing facility in Andhra Pradesh received two U.S. FDA observations during a recent inspection.
- Dr. Reddy's Laboratories slides Thursday, outperforms competitors
Dr. Reddy's Laboratories shares declined 1.86% to 1,180.00 Indian rupees on Thursday amidst a general market downturn.
- A 10 a.m. ET earnings call is scheduled for October 23 at Dr. Reddy’s (RDY).
Dr. Reddy's Laboratories will release its Q2FY27 financial results on October 23, 2026, followed by an earnings call.
- Dr Reddy's Share Price: वित्त वर्ष बताने में गलती अमेरिकी इकाई पर पड़ी भारी, अब 5 अक्टूबर को शेयर फोकस में
Dr. Reddy's Laboratories' US subsidiary was fined $32,350.20 by the IRS for an incorrect financial year reference during tax payment.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Dr. Reddy's Laboratories?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies